Sanofi (SNY) | Common-Size Income Statement
See also
- Johnson & Johnson (JNJ), Common-Size Income Statement
- Pfizer Inc. (PFE), Common-Size Income Statement
- Novartis AG (NVS), Common-Size Income Statement
- Merck & Co. Inc. (MRK), Common-Size Income Statement
- GlaxoSmithKline PLC (GSK), Common-Size Income Statement
- Abbott Laboratories (ABT), Common-Size Income Statement
- Novo Nordisk A/S (NVO), Common-Size Income Statement
- UnitedHealth Group Inc. (UNH), Common-Size Income Statement
- Bristol-Myers Squibb Co. (BMY), Common-Size Income Statement
- AstraZeneca PLC (AZN), Common-Size Income Statement
- Eli Lilly & Co. (LLY), Common-Size Income Statement
- Medtronic Inc. (MDT), Common-Size Income Statement
- Baxter International Inc. (BAX), Common-Size Income Statement
ˇ Show More
You have visited 10 password protected pages for free. Others contain data covered by 
.
Sign Up Now to get full access to whole website and cut out all advertisements.
Sanofi, Common-Size Consolidated Income Statement
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | ||
|---|---|---|---|---|---|---|
 |
Net sales | |
|
|
|
|
|
Other revenues | |
|
|
|
|
|
Cost of sales | |
|
|
|
|
|
Gross profit | % |
% |
% |
% |
% |
|
Research and development expenses | |
|
|
|
|
|
Selling and general expenses | |
|
|
|
|
|
Other operating income | |
|
|
|
|
|
Other operating expenses | |
|
|
|
|
|
Amortization of intangible assets | |
|
|
|
|
|
Impairment of intangible assets | |
|
|
|
|
|
Fair value remeasurement of contingent consideration liabilities | |
|
|
|
|
|
Restructuring costs | |
|
|
|
|
|
Other gains and losses, and litigation | |
|
|
|
|
|
Operating income | % |
% |
% |
% |
% |
|
Cost of debt | |
|
|
|
|
|
Interest income | |
|
|
|
|
|
Cost of debt, net of cash and cash equivalents | % |
% |
% |
% |
% |
|
Non-operating foreign exchange gains (losses) | |
|
|
|
|
|
Fair value gains (losses) on other derivatives | |
|
|
|
|
|
Unwinding of discount on provisions | |
|
|
|
|
|
Gains (losses) on disposals of financial assets | |
|
|
|
|
|
Impairment losses on financial assets, net of reversals | |
|
|
|
|
|
Other items | |
|
|
|
|
|
Net financial income (expenses) | % |
% |
% |
% |
% |
|
Income before tax and associates and joint ventures | % |
% |
% |
% |
% |
|
Income tax expense | |
|
|
|
|
|
Share of profit (loss) of associates and joint ventures | |
|
|
|
|
|
Net income excluding the held-for-exchange Merial business | % |
% |
% |
% |
% |
|
Net income from the held-for-exchange Merial business | |
|
|
|
|
|
Net income | % |
% |
% |
% |
% |
|
Net income attributable to non-controlling interests | |
|
|
|
|
|
Net income attributable to equity holders of Sanofi | % |
% |
% |
% |
% |
Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center